IDH2 and central nervous system cancer: More recently, Franceschi E et al. [11] observed a favorable prognostic impact of IDH1 G105G SNP in a series of IDH-mutant grade 2/3 gliomas (PFS: not reached vs. 47.3 months, p = 0.015); multivariate analysis confirmed this finding (HR 0.240; CI = 0.074–0.784, p = 0.018), but the main limitation of this study is the limited number of patients (71 patients, 9 SNP carriers), which precludes any firm conclusion.